多发性内分泌腺瘤病1型患者静脉血栓栓塞风险增加
该研究基于286例生殖系突变阳性的多发性内分泌腺瘤病1型(MEN1)患者的前瞻性自然史研究,分析1991至2019年静脉血栓栓塞(VTE)事件,发现VTE患病率为12.9%,年龄-性别调整后发病率为每1000患者年9.11,终身发病率约高于普通人群2倍,作者认为MEN1患者VTE风险增加。
要点
- MEN1患者VTE患病率为12.9%,年龄-性别调整后发病率为每1000患者年9.11。
- MEN1相关VTE的终身发病率约为普通人群估计年发病率的2倍,与多种癌症已知风险相当。
- 发生VTE的患者中约80%诊断为胰腺神经内分泌肿瘤,其中24%为胰岛素瘤。
核心结论
- MEN1患者VTE风险增加,但需进一步机制研究和其他MEN1队列验证。
研究设计与样本
- 查询1991至2019年前瞻性自然史研究中生殖系突变阳性MEN1患者(n=286)的所有VTE终生事件。
主要发现
- 36例受试者(中位年龄45岁,范围16-75)发生VTE事件,患病率为12.9%。
- VTE年龄-性别调整发病率为每1000患者年9.11,性别调整终身发病率为每1000患者年2.81。
- MEN1相关终身发病率约为普通人群估计年发病率的2倍,与多种癌症已知风险相当。
- 发生VTE的患者中约80%诊断为胰腺神经内分泌肿瘤,其中24%为胰岛素瘤。
- 14例患者(42%)发生围手术期VTE事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步机制研究和其他MEN1队列的验证以确认MEN1中VTE患病率增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiple endocrine neoplasia type 1 (MEN1) is a rare inherited disorder predisposing the development of multiple functional and nonfunctional neuroendocrine tumors (NETs). Only uncommon MEN1-associated functional NETs such as glucagonomas (<1%) and adenocorticotropic hormone-producing tumors (<5%) are known to be associated with hypercoagulability. It is unknown if patients with MEN1 generally have an increased risk of venous thromboembolism (VTE). METHODS: We queried a prospective natural history study of germline mutation-positive MEN1 patients (n = 286) between 1991 and 2019 for all lifetime events of VTE. The search terms were: DVT, thromb, embol, PE, pulmonary embolism, clot, hematology consult, anticoagulant, coumadin, lovenox, xarelto, warfarin, aspirin, rivaroxaban, and apixaban. Incidence rates were calculated, accounting for age and sex. Comparisons were made to published incidence rates in healthy populations, different types of cancer, and Cushing's syndrome. RESULTS: Thirty-six subjects (median age 45 years, range 16-75) experienced a VTE event, yielding a prevalence rate of 12.9%. The age-sex adjusted incidence rate of VTE is 9.11 per 1000 patient-years, with a sex-adjusted lifetime incidence rate of 2.81 per 1000 patient-years. MEN1-associated lifetime incidence rates are ~2-fold higher than the estimated annual incidence rate in the general population and are comparable to the known risk in the setting of various types of cancer. Approximately 80% of patients who had a VTE were diagnosed with pancreatic NETs, of which 24% were insulinomas. Fourteen patients (42%) experienced perioperative VTE events. CONCLUSIONS: MEN1 patients have an increased risk of VTE. Further mechanistic investigation and validation from other MEN1 cohorts are needed to confirm the increased prevalence of VTE in MEN1.
引用
- Lee ME, Ortega-Sustache YM, Agarwal SK, et al. Patients With MEN1 Are at an Increased Risk for Venous Thromboembolism. J Clin Endocrinol Metab. 2021. PMID: 32756962. doi:10.1210/clinem/dgaa501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。